Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

FDA approves Advair Diskus for treatment of asthma

Aug. 28, 2000

Neurokinin antagonists under development for treatment of respiratory diseases

Aug. 28, 2000

Theratechnologies to commence phase II trial of ThGRF1-44 in COPD

Aug. 25, 2000

Orally active nonpeptide NK1 antagonist selected by Fujisawa for clinical testing

Aug. 24, 2000

Schering-Plough receives extended marketing exclusivity, submits sNDAs for loratadine

Aug. 24, 2000

Bayer and PPL Therapeutics to jointly develop aerosol AAT formulation

Aug. 24, 2000

Chiron to acquire PathoGenesis; TOBI clears E.U. mutual recognition process

Aug. 23, 2000

New VLA-4 inhibitors under development at Aventis

Aug. 23, 2000

Novel VLA-4 inhibitors reported by Elan and Wyeth-Ayerst

Aug. 23, 2000

Orally active dual NK1/NK2 antagonist synthesized by Schering-Plough

Aug. 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...